Summary
The disposition and plasma protein binding of quinidine after intravenous administration were studied in 13 healthy subjects. Plasma protein binding, expressed as the fraction of quinidine unbound ranged from 0.134–0.303 (mean 0.221). Elimination rate constant (β) varied from 0.071 to 0.146 h−1 (mean 0.113), and apparent volume of distribution (Vβ) varied from 1.39–3.20 l · kg−1β (mean 2.27). Total body clearance was 2.32–6.49 ml min−1 · kg−1. There was a positive linear correlation between the plasma fraction of unbound quinidine and both Vβ (r=0.885, p<0.01) and total body clearance (r=0.668, p<0.05). No significant correlation existed between the fraction of unbound quinidine in plasma and the elimination rate constant. The results show that both the apparent volume of distribution and total body clearance of quinidine are proportional to the unbound fraction in plasma. This implies that the total plasma concentration of quinidine at steady state will change with alterations in plasma binding, whilst the concentration of unbound compund and its elimination rate will remain unaffected.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bickel, M.H., Steele, J.W.: Binding of basic and acidic drugs to rat tissue subcellular fractions. Chem. Biol. Interact.8, 151–162 (1974)
Bolme, P., Otto, U.: Dose-dependence of the pharmacokinetics of quinidine. Europ. J. clin. Pharmacol.12, 73–76 (1977)
Conrad, K.A., Molk, B.L., Chidsey, C.A.: Pharmacokinetic studies of quinidine in patients with arrhythmias. Circulation55, 1–7 (1977)
Cramér, G.: Early and late results of conversion of atrial fibrillation with quinidine. A clinical and hemodynamic study. Acta med. scand. Suppl.490, (1968)
Cramér, G., Isaksson, B.: Quantitative determination of quinidine in plasma. Scand. J. clin. Lab. Invest.15, 553–556 (1963)
Crouthamel, W.G.: The effect of congestive heart failure on quinidine pharmacokinetics. Am. Heart. J.90, 335–339 (1975)
Fremstad, D., Bergerud, K., Haffner, J.F.W., Lunde, P.K.M.: Increased plasma binding of quinidine after surgery: a preliminary report. Europ. J. clin. Pharmacol.10, 441–444 (1976)
Gibaldi, M., Perrier, D.: Pharmacokinetics, p. 322. New York: Marcel Dekker 1975
Greenblatt, D.J., Pfeifer, H.J., Ochs, H.R., Franke, K., MacLaughlin, D.S., Smith, T.W., Koch-Weser, J.: Pharmacokinetics of quinidine in humans after intravenous, intramuscular and oral administration. J. Pharmacol. exp. Ther.202, 365–378 (1977)
Härtel, G., Harjanne, A.: Comparison of two methods for quinidine determination and chromatographic analysis of the difference. Clin. Chem. Acta23, 289–294 (1969)
Härtel, G., Korhonen, A.: Thin layer chromatography for the quantitative separation of quinidine and quinidine metabolites from biological fluids and tissues. J. Chromatogr.37, 70–75 (1968)
Huffman, D.H., Hignite, C.E.: Serum quinidine concentrations: comparison of fluorescence, gas-chromatographic and gas-chromatographic/mass-spectrometric methods. Clin. Chem.22, 810–812 (1976)
Kates, R.E., Sokoloski, T.D., Comstock, T.J.: Binding of quinidine to plasma proteins in normal subjects and in patients with hyperlipoproteinemias. Clin. Pharmacol. Ther.23, 30–35 (1978)
Levy, G.: Clinical implications of interindividual differences in plasma protein binding of drug and endogenous substances. In: The Effect of Disease States on Drug Pharmacokinetics. L.Z. Benet (ed.), pp. 137–151. Washington: American Pharmaceutical Association Academy of Pharmaceutical Sciences, 1976
Nilsen, O.G.: Serum albumin and lipoproteins as the quinidine binding molecules in normal human sera. Biochem. Pharmacol.25, 1007–1012 (1976)
Nilsen, O.G., Jacobsen, S.: The binding of quinidine to protein fractions of normal human sera. Biochem. Pharmacol.24, 995–998 (1975)
Nilsen, O.G., Leren, P., Aakesson, I., Jacobsen, S.: Binding of quinidine in sera with different levels of triglycerides, cholesterol and orosomucoid protein. Biochem. Pharmacol.27, 871–876 (1978)
Shand, D.G., Mitchell, J.R., Oates, J.A.: Pharmacokinetic drug interactions. In: Concepts in Biochemical Pharmacology. J.R. Gillette and J.R. Mitchell (eds.), pp. 272–307. Berlin-Heidelberg-New York: Springer 1975
Sokolow, M., Ball, R.E.: Factors influencing conversion of chronic atrial fibrillation with special reference to serum quinidine concentration. Circulation14, 568–583 (1956)
Ueda, C.T., Hirschfeld, D.S., Scheinman, M.M., Rowland, M., Williamson, B.J., Dzindzio, B.S.: Disposition kinetics of quinidine. Clin. Pharmacol. Ther.19, 30–36 (1976a)
Ueda, C.T., Williamson, B.J., Dzindzio, B.S.: Absolute quinidine bioavailability. Clin. Pharmacol. Ther.20, 260–265 (1976b)
Ueda, C.T., Williamson, B.J., Dzindzio, B.S.: Disposition kinetics of dihydroquinidine following quinidine administration. Res. Commun. Chem. Pathol. Pharmacol.14, 215–225 (1976c)
Westphal, U.: Steroid-protein interactions, pp. 553. Berlin-Heidelberg-New York: Springer 1971
Wilkinson, G.R., Shand, D.G.: Commentary. A physiological approach to hepatic drug clearance. Clin. Pharmacol. Ther.18, 377–390 (1975)
Yacobi, A., Levy, G.: Comparative pharmacokinetics of coumarin anticoagulants XIV: relationship between protein binding, distribution and elimination kinetics of warfarin in rats. J. Pharm. Sci.64, 1660–1664 (1975)
Yacobi, A., Udall, J.A., Levy, G.: Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect. Clin. Pharmacol. Ther.19, 552–558 (1976)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fremstad, D., Nilsen, O.G., Storstein, L. et al. Pharmacokinetics of quinidine related to plasma protein binding in man. Eur J Clin Pharmacol 15, 187–192 (1979). https://doi.org/10.1007/BF00563104
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00563104